Real-world experience with cefepime/zidebactam under compassionate use

Introduction: Cefepime/zidebactam is a β-lactam/β-lactam enhancer combination with activity against carbapenem-resistant (CR) Gram-negative pathogens, including metallo-β-lactamase (MBL)-producing organisms. Before regulatory approval, cefepime/zidebactam was available through a compassionate-use programme for patients with CR Gram-negative infections who had limited available treatment options. Methods: We conducted a retrospective, multi-country analysis of patients who received cefepime/zidebactam through compassionate use between 2022 and 2025. Data included demographics, comorbidities, acute complications, prior antibiotic exposure, infection characteristics, microbiology, treatment details, and investigator-assessed outcomes. Results: Eighty-five patients were included (median age 48 years; 57.6% in an intensive care unit at initiation). Primary infections included pneumonia/respiratory infection (30.6%), bone and joint infection (24.7%), and complicated urinary tract infection/pyelonephritis (14.1%). Pseudomonas aeruginosa was the predominant pathogen (77.6%), followed by Klebsiella pneumoniae (14.1%) and Acinetobacter baumannii (11.8%); infections involving at least two Gram-negative pathogens occurred in 10.6%. Among isolates with available genotypic data, MBLs were common and predominantly NDM. The cefepime/zidebactam minimum inhibitory concentration (MIC)50 and MIC90 were 8 and 32 mg/L, respectively. Investigator-assessed clinical success at the end of therapy was achieved in 88.2% of patients (95% CI, 79.7–93.5), and microbiological eradication in 89.4% (95% CI, 81.1–94.3); on-therapy mortality was 10.6% (95% CI, 5.7–18.9). Treatment-emergent adverse events occurred in five patients (5.9%, 95% CI, 2.5–13.0), with one discontinuation. Conclusions: In this uncontrolled compassionate-use case series, cefepime/zidebactam treatment was accompanied by high investigator-assessed clinical success and microbiological eradication in patients with severe infections caused by CR Gram-negative pathogens. These observations require confirmation in prospective controlled studies.

Authors

Institutions

Publication Details

Journal
UNC Libraries
Published
2026-11-17
DOI
https://doi.org/10.17615/9bwt-te51
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-world experience with cefepime/zidebactam under compassionate use

Surabhi Madan, Vijil Rahulan, Sowmya Sridharan, Anjely Pulparampil Sebastian et al.
3 links
UNC Libraries
Antibiotic Resistance in Bacteria
article

Real-world experience with cefepime/zidebactam under compassionate use

Surabhi Madan, Vijil Rahulan, Sowmya Sridharan, Anjely Pulparampil Sebastian, Siddhant Shetty, William R. Miller, Kedar Toraskar, Vishnu Rao Polati, Manish Soneja, Sandeep Kumar Mitra, Praveen Kumar Tirlangi, Harshith B. Kadnur, Timothy William, Honey Satish Savla, Radhika Sarda, Balaji Veeraraghavan, Vidya Krishna, Abi Manesh S, Suneetha Narreddy, Monalisa Sahu, David van Duin, Nitin Ranjan Gupta, Erlinda Rose Ulloa, Umang Agrawal, Harshad S Limaye, Ayesha Sunavala, Thomas P. Lodise, Elisabeth E. Adderson, Tanu Singhal, Samuel L Aitken, Dilip Kumar Dubey, Vikas Deswal, Subramanian Swaminathan, Nitin Bansal, Pooja H Shah, Raman Gaikwad, Shalmali B Inamdar, Irfana Mohammed, Ashwini R Tayade, Pratik Y Patil, Rajeev Soman, Abdul Ghafur, Rasika Sirsat, Vasant Nagvekar, Neha Gupta, Andrew Shorr, Ankit Mittal
article en

Abstract

Introduction: Cefepime/zidebactam is a β-lactam/β-lactam enhancer combination with activity against carbapenem-resistant (CR) Gram-negative pathogens, including metallo-β-lactamase (MBL)-producing organisms. Before regulatory approval, cefepime/zidebactam was available through a compassionate-use programme for patients with CR Gram-negative infections who had limited available treatment options. Methods: We conducted a retrospective, multi-country analysis of patients who received cefepime/zidebactam through compassionate use between 2022 and 2025. Data included demographics, comorbidities, acute complications, prior antibiotic exposure, infection characteristics, microbiology, treatment details, and investigator-assessed outcomes. Results: Eighty-five patients were included (median age 48 years; 57.6% in an intensive care unit at initiation). Primary infections included pneumonia/respiratory infection (30.6%), bone and joint infection (24.7%), and complicated urinary tract infection/pyelonephritis (14.1%). Pseudomonas aeruginosa was the predominant pathogen (77.6%), followed by Klebsiella pneumoniae (14.1%) and Acinetobacter baumannii (11.8%); infections involving at least two Gram-negative pathogens occurred in 10.6%. Among isolates with available genotypic data, MBLs were common and predominantly NDM. The cefepime/zidebactam minimum inhibitory concentration (MIC)50 and MIC90 were 8 and 32 mg/L, respectively. Investigator-assessed clinical success at the end of therapy was achieved in 88.2% of patients (95% CI, 79.7–93.5), and microbiological eradication in 89.4% (95% CI, 81.1–94.3); on-therapy mortality was 10.6% (95% CI, 5.7–18.9). Treatment-emergent adverse events occurred in five patients (5.9%, 95% CI, 2.5–13.0), with one discontinuation. Conclusions: In this uncontrolled compassionate-use case series, cefepime/zidebactam treatment was accompanied by high investigator-assessed clinical success and microbiological eradication in patients with severe infections caused by CR Gram-negative pathogens. These observations require confirmation in prospective controlled studies.

UNC Libraries
University of North Carolina at Chapel Hill (US)
Purdue University, California Institute of Technology, Gun och Bertil Stohnes Stiftelse, Wellcome Trust, Ögonfonden, Stiftelsen Tornspiran, Ohio Soybean Council, Heritage Medical Research Institute, National Energy Research Scientific Computing Center, University of Leeds, Indian Council of Medical Research, Deutsche Forschungsgemeinschaft, National Natural Science Foundation of China, China Postdoctoral Science Foundation, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, China Scholarship Council, Norges Forskningsråd, Suzhou Municipal Science and Technology Bureau, Gansu University of Chinese Medicine, Narodowa Agencja Wymiany Akademickiej, Agencia Nacional de Investigación y Desarrollo, Ministero dell'Università e della Ricerca, National Institutes of Health, Office of Science, Engineering and Physical Sciences Research Council, Basic Research Program of Jiangsu Province, Sanming Project of Medicine in Shenzhen, National Key Research and Development Program of China, Institute for Materials Research, Tohoku University, National Heart, Lung, and Blood Institute, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases, Office of Advanced Cyberinfrastructure, Division of Chemical, Bioengineering, Environmental, and Transport Systems, Basic Energy Sciences, Fondo Nacional de Desarrollo Científico y Tecnológico, H2020 European Research Council
Good health and well-being
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon